La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Celltrion Bilan de santé

Santé financière contrôle des critères 6/6

Celltrion possède un total de capitaux propres de ₩16,993.9B et une dette totale de ₩2,143.3B, ce qui porte son ratio d'endettement à 12.6%. Son actif total et son passif total sont ₩20,127.1B et de ₩3,133.2B. L'EBIT de Celltrion est ₩373.9B ce qui fait que son ratio de couverture des intérêts 22.3. Elle dispose de liquidités et de placements à court terme de ₩1,030.8B.

Informations clés

12.6%

Ratio d'endettement

₩2.14t

Dette

Ratio de couverture des intérêts	22.3x
Argent liquide	₩1.03t
Fonds propres	₩16.99t
Total du passif	₩3.13t
Total des actifs	₩20.13t

Mises à jour récentes de la santé financière

Recent updates

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Jun 26

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

May 22

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Apr 30

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Mar 25

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Mar 19

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

May 05

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Mar 25

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de A068270 ( ₩5,229.7B ) dépassent ses passifs à court terme ( ₩2,889.4B ).

Passif à long terme: Les actifs à court terme de A068270 ( ₩5,229.7B ) dépassent ses passifs à long terme ( ₩243.8B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de A068270 ( 6.5% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de A068270 a été réduit de 18.9% à 12.6% au cours des 5 dernières années.

Couverture de la dette: La dette de A068270 est bien couverte par le flux de trésorerie opérationnel ( 20.2% ).

Couverture des intérêts: Les paiements d'intérêts de A068270 sur sa dette sont bien couverts par l'EBIT ( 22.3 x couverture).

Celltrion Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Recent updates

Consensus EPS estimates fall by 21%

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024

Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

First quarter 2024 earnings released: EPS: ₩108 (vs ₩1,156 in 1Q 2023)

Now 21% overvalued after recent price rise

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Consensus EPS estimates fall by 14%

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Full year 2023 earnings released: EPS: ₩3,759 (vs ₩3,664 in FY 2022)

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Consensus EPS estimates fall by 16%

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease (IBD)

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩500 per share at 0.3% yield

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Celltrion Healthcare Announces Canadian Approval of Vegzelma® (Bevacizumab for Injection) for the Treatment of Five Types of Cancer

Upcoming dividend of ₩375 per share

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: ₩1,328 (vs ₩907 in 2Q 2021)

Price target increased to ₩210,861

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,520

Less than half of directors are independent

Now 20% undervalued after recent price drop

Price target decreased to ₩218,897

Full year 2021 earnings: EPS misses analyst expectations

Consensus revenue estimates increase by 10%

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Price target decreased to ₩277,071

Third quarter 2021 earnings released: EPS ₩992 (vs ₩1,251 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ₩919 (vs ₩1,013 in 2Q 2020)

Consensus EPS estimates fall to ₩4,214

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Celltrion, Inc. Receives FDA Emergency Use Authorization for Point of Care Antigen Rapid Test Kit – DiaTrust COVID-19 Ag Rapid Test

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

New 90-day low: ₩300,500

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform

Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Celltrion Group Announces Positive Top-Line Efficacy and Safety Data from Global Phase II/III Clinical Trial of COVID-19 Treatment Candidate CT-P59

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Celltrion, Inc. (KOSE:A068270) completed the acquisition of portfolio of select non-core otc and prescription pharmaceutical products exclusively in Asia Pacific from Takeda Pharmaceutical Company Limited (TSE:4502).

Celltrion Completes Enrolment for Global Phase II Clinical Trial with COVID-19 Treatment Candidate CT-P59

New 90-day high: ₩330,000

Celltrion Presents Efficacy and Safety Data for Potential Covid-19 Treatment Candidate Ct-P59 in Patients with Mild Symptoms

New 90-day low: ₩245,500

New 90-day low: ₩278,500

Price target raised to ₩284,353

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines